CLINICAL TRIAL: TRIAL OF METFORMIN IN OBESE ADOLESCENTSMETFORMIN IN OBESE ADOL

临床试验：二甲双胍治疗肥胖青少年的试验二甲双胍治疗肥胖青少年的试验

• 批准号: 7717854
• 负责人: DARRELL M WILSON
• 金额: $ 0.15万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7717854
• 关键词: 18 year old; Adolescent; Age; American; Body mass index; Cholesterol; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Coupled; Data; Diabetes Mellitus; Epidemic; Funding; Grant; Guidelines; Health; Height; High Blood Pressure; Individual; Institution; Measures; Metformin; Numbers; Obesity; Placebos; Population; Randomized; Research; Research Personnel; Resources; Source; Testing; United States National Institutes of Health; Weight; Youth; base; glucophage; lifestyle intervention

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Currently, there is an epidemic of obesity among American youth. As a result, health problems related to obesity, such as high blood pressure, elevated cholesterol levels and diabetes, have increased among this population as well. A number of adolescents have been and are currently being treated for obesity with metformin, despite a lack of scientific data supporting its use. This trial will test the hypothesis that among obese adolescents, treatment with extended-release metformin (Glucophage XR), coupled with a lifestyle intervention, will result in decreased obesity as compared to subjects who receive treatment with placebo and the same lifestyle intervention. Approximately 135 potential subjects will be screened in order to randomize 76 obese adolescents between the ages of 13-18 years old. Obesity will be assessed by measuring each subject's Body Mass Index (BMI). BMI provides a guideline based on weight and height to determine whether an individual is at an appropriate weight.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 目前，肥胖症在美国青年中流行。 因此，与肥胖有关的健康问题，如高血压、胆固醇水平升高和糖尿病，在这一人群中也有所增加。许多青少年已经和目前正在接受二甲双胍治疗肥胖，尽管缺乏支持其使用的科学数据。 本试验将检验以下假设：在肥胖青少年中，与接受安慰剂治疗和相同生活方式干预的受试者相比，二甲双胍缓释剂（格华止XR）治疗联合生活方式干预将导致肥胖减少。 将筛选约135例潜在受试者，以随机分配76例13-18岁的肥胖青少年。 将通过测量每例受试者的体重指数（BMI）评估肥胖。BMI提供了基于体重和身高的指南，以确定个人是否处于适当的体重。